Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 675

1.

Efficacy and safety of rituximab for autoimmune neutropenia: a French case series and literature review.

Bigot W, Viallard JF, Sellam J, Dellal A, Retbi A, Gobert D, Malard F, Mohty M, Mekinian A, Fain O.

Rheumatology (Oxford). 2020 Feb 21. pii: keaa045. doi: 10.1093/rheumatology/keaa045. [Epub ahead of print] No abstract available.

PMID:
32083652
2.

Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.

El-Cheikh J, Labopin M, Al-Chami F, Bazarbachi A, Angelucci E, Santarone S, Bonifazi F, Carella AM, Castagna L, Bruno B, Iori AP, La Nasa G, Savani B, Nagler A, Mohty M.

Clin Lymphoma Myeloma Leuk. 2020 Jan 27. pii: S2152-2650(20)30044-6. doi: 10.1016/j.clml.2020.01.007. [Epub ahead of print]

PMID:
32081702
3.

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.

Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2020 Feb 17. doi: 10.1038/s41409-020-0826-4. [Epub ahead of print]

PMID:
32066864
4.

Old Dog, New Trick: Trivalent Arsenic as an Immunomodulatory Drug.

Ye Y, Gaugler B, Mohty M, Malard F.

Br J Pharmacol. 2020 Feb 5. doi: 10.1111/bph.15011. [Epub ahead of print] Review.

PMID:
32022256
5.

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.

Díaz-Beyá M, Labopin M, Maertens J, Alijurf M, Passweg J, Dietrich B, Schouten H, Socié G, Schaap N, Schwerdtfeger R, Volin L, Michallet M, Polge E, Sierra J, Mohty M, Esteve J, Nagler A; Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Br J Haematol. 2020 Feb 5. doi: 10.1111/bjh.16433. [Epub ahead of print]

PMID:
32020596
6.

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak GW.

Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X. Review.

PMID:
32004485
7.

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients.

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M.

Bone Marrow Transplant. 2020 Jan 29. doi: 10.1038/s41409-020-0803-y. [Epub ahead of print]

PMID:
31996792
8.

Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.

Stocker N, Gaugler B, Ricard L, de Vassoigne F, Marjanovic Z, Mohty M, Malard F.

Cancer Med. 2020 Jan 28. doi: 10.1002/cam4.2827. [Epub ahead of print]

9.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel.

Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, Mohty M, Nagler A, Passweg J, Rambaldi A, Socie G, Solano C, Walker I, Barosi G, Kröger N.

Bone Marrow Transplant. 2020 Jan 22. doi: 10.1038/s41409-020-0792-x. [Epub ahead of print]

PMID:
31969678
10.

An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.

Al-Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SOA.

Blood Adv. 2020 Jan 14;4(1):229-238. doi: 10.1182/bloodadvances.2019000168.

11.

Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy.

Fuji S, Nagler A, Mohty M, Savani B, Shouval R.

Bone Marrow Transplant. 2020 Jan 13. doi: 10.1038/s41409-020-0784-x. [Epub ahead of print] Review.

PMID:
31932655
12.

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.

Bazarbachi A, Labopin M, Angelucci E, Gülbas Z, Ozdogu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, Martino M, Ciceri F, Koç Y, Socié G, Blaise D, Herrera C, Chalandon Y, Bernasconi P, Marotta G, Castagna L, McDonald A, Visani G, Carluccio P, Vitek A, Simand C, Afanasyev B, Rösler W, Diez-Martin JL, Nagler A, Brissot E, Giebel S, Mohty M.

Biol Blood Marrow Transplant. 2020 Jan 9. pii: S1083-8791(20)30013-6. doi: 10.1016/j.bbmt.2020.01.003. [Epub ahead of print]

PMID:
31926364
13.

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.

Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A.

Leukemia. 2020 Jan 9. doi: 10.1038/s41375-019-0694-3. [Epub ahead of print] Review.

PMID:
31919472
14.

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation.

Poiré X, Labopin M, Polge E, Volin L, Finke J, Ganser A, Blaise D, Yakoub-Agha I, Beelen D, Forcade E, Lioure B, Socié G, Niederwieser D, Labussière-Wallet H, Maertens J, Cornelissen J, Craddock C, Mohty M, Esteve J, Nagler A.

Am J Hematol. 2020 Mar;95(3):282-294. doi: 10.1002/ajh.25714. Epub 2020 Jan 17.

PMID:
31876307
15.

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, Deconinck E.

Blood Adv. 2019 Dec 23;3(24):4238-4251. doi: 10.1182/bloodadvances.2019000647.

16.

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.

Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, Belhadj K, Facon T, Hulin C, Mohty M, Fontan J, Macro M, Brechignac S, Jaccard A, Stoppa AM, Orsini-Piocelle F, Adiko D, Voillat L, Keddar F, Barry M, Demarquette H, Certain MN, Plantier I, Roussel M, Hébraud B, Filleron T, Attal M, Avet-Loiseau H.

Haematologica. 2019 Dec 19. pii: haematol.2019.236588. doi: 10.3324/haematol.2019.236588. [Epub ahead of print] No abstract available.

17.

Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial.

Peffault de Latour R, Chevret S, Ruggeri AL, Suarez F, Souchet L, Michonneau D, Sicre de Fontbrune F, Coman T, Dhedin N, Rubio MT, Nguyen S, Mohty M, Socié G.

Blood. 2020 Jan 16;135(3):227-229. doi: 10.1182/blood.2019000358. No abstract available.

PMID:
31805185
18.
19.

Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Passweg JR, Labopin M, Christopeit M, Cornelissen J, Pabst T, Socié G, Russel N, Yakoub-Agha I, Blaise D, Gedde-Dahl T, Labussière-Wallet H, Malladi R, Forcade E, Maury S, Polge E, Lanza F, Gorin NC, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Nov 21. pii: S1083-8791(19)30788-8. doi: 10.1016/j.bbmt.2019.11.021. [Epub ahead of print]

PMID:
31759159
20.

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Nov 21. doi: 10.1038/s41409-019-0740-9. [Epub ahead of print]

PMID:
31754251
21.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Haematologica. 2020 Jan 31;105(2):297-316. doi: 10.3324/haematol.2019.229781. Print 2020.

22.

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT.

Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, Gramatzki M, Stelljes M, Blaise D, Stoelzel F, Chevallier P, Holler E, Fegueux N, Mohty M, Nagler A.

Blood Cancer J. 2019 Nov 18;9(12):88. doi: 10.1038/s41408-019-0251-3.

23.

The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.

Nagler A, Dholaria B, Labopin M, Socie G, Huynh A, Itälä-Remes M, Deconinck E, Yakoub-Agha I, Cahn JY, Bourhis JH, Labussière-Wallet H, Chantepie S, Esteve J, Savani B, Mohty M.

Leukemia. 2019 Nov 14. doi: 10.1038/s41375-019-0631-5. [Epub ahead of print]

PMID:
31728052
24.

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia.

Gratwohl A, Duarte R, Snowden JA, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix HT, Grath EM, Mohty M, Kroeger N, Nagler A, Niederwieser D, Putter H, Brand R; Joint Accreditation Committee JACIE.

EClinicalMedicine. 2019 Aug 9;15:33-41. doi: 10.1016/j.eclinm.2019.07.019. eCollection 2019 Oct.

25.

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant.

Bazarbachi AH, Al Hamed R, Malard F, Mohty M, Bazarbachi A.

Ther Adv Hematol. 2019 Nov 1;10:2040620719882666. doi: 10.1177/2040620719882666. eCollection 2019. Review.

26.

Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process.

Papageorgiou L, Alhaj Hussen K, Thouroude S, Mbemba E, Cost H, Garderet L, Elalamy I, Larsen A, Van Dreden P, Dimopoulos MA, Mohty M, Gerotziafas GT.

TH Open. 2019 Nov 4;3(4):e340-e347. doi: 10.1055/s-0039-1700885. eCollection 2019 Oct.

27.

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.

Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, Chabannon C, Kharfan-Dabaja MA, Savani BN, Huang H, Kenderian S, Nagler A, Perales MA.

Leukemia. 2019 Dec;33(12):2767-2778. doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5. Review.

PMID:
31690821
28.

Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.

Peric Z, Mohty R, Bastos J, Brissot E, Battipaglia G, Belhocine R, Sestili S, Giannotti F, Vekhoff A, Ledraa T, Legrand O, Lapusan S, Isnard F, Labopin M, Bonnin A, Mediavilla C, Rubio MT, Ruggeri A, Duléry R, Malard F, Mohty M.

Bone Marrow Transplant. 2019 Oct 31. doi: 10.1038/s41409-019-0726-7. [Epub ahead of print]

PMID:
31673080
29.

Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor.

Deteix C, Mesnil F, Furst S, Milpied N, Yakoub-Agha I, Fegueux N, Latour RP, Mohty M, Chevallier P, Labussière Wallet H, Huynh A, Larosa F, Bourhis JH, Cahn JY, Chantepie S, Bay JO, Audat F, Foote A, Faucher C, Marry E, Garban F; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Bone Marrow Transplant. 2019 Oct 29. doi: 10.1038/s41409-019-0722-y. [Epub ahead of print]

PMID:
31664184
30.

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.

Pavlů J, Labopin M, Niittyvuopio R, Socié G, Yakoub-Agha I, Wu D, Remenyi P, Passweg J, Beelen DW, Aljurf M, Kröger N, Labussière-Wallet H, Perić Z, Giebel S, Nagler A, Mohty M.

J Hematol Oncol. 2019 Oct 23;12(1):108. doi: 10.1186/s13045-019-0790-x.

31.

Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.

Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Oct 23. doi: 10.1038/s41409-019-0720-0. [Epub ahead of print]

PMID:
31645668
32.

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, McGrath E, Brook N, de Elvira CR, Gordon D, Poirel HA, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo JD, Spellman SR, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak GW, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour RP, Kroeger N, Brand R, de Wreede LC, van Zwet E, Putter H.

Bone Marrow Transplant. 2019 Oct 21. doi: 10.1038/s41409-019-0718-7. [Epub ahead of print] Erratum in: Bone Marrow Transplant. 2019 Nov 21;:.

PMID:
31636397
33.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.

Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A.

Br J Haematol. 2020 Feb;188(3):428-437. doi: 10.1111/bjh.16185. Epub 2019 Oct 14.

PMID:
31612473
34.

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.

Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Basak G, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Dignan F, Fukuda T, Huynh A, Kuball J, Lachance S, Lazarus H, Masszi T, Michallet M, Nagler A, NiChonghaile M, Okamoto S, Pagliuca A, Peters C, Petersen FB, Richardson PG, Ruutu T, Saber W, Savani BN, Soiffer R, Styczynski J, Wallhult E, Yakoub-Agha I, Duarte RF, Carreras E.

Bone Marrow Transplant. 2019 Oct 1. doi: 10.1038/s41409-019-0705-z. [Epub ahead of print] No abstract available.

PMID:
31576023
35.

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.

Bazarbachi AH, Al Hamed R, Labopin M, Afanasyev B, Hamladji RM, Beelen D, Eder M, Scheid C, Wu D, Bunjes D, Stepensky P, Tischer J, Kröger N, Peric Z, Aljurf M, Giebel S, Nagler A, Mohty M.

Bone Marrow Transplant. 2019 Sep 27. doi: 10.1038/s41409-019-0702-2. [Epub ahead of print]

PMID:
31562398
36.

Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes.

Stocker N, Labopin M, Boussen I, Paccoud O, Bonnin A, Malard F, Amiel C, Gozlan J, Battipaglia G, Duléry R, Giannotti F, Ruggeri A, Gaugler B, Mohty M, Brissot E.

Bone Marrow Transplant. 2019 Sep 27. doi: 10.1038/s41409-019-0699-6. [Epub ahead of print]

PMID:
31562397
37.

A novel mouse model of acute graft-versus-host disease based on chemotherapy conditioning and G-CSF mobilized graft.

Ye Y, Ricard L, Stocker N, Mohty M, Gaugler B, Malard F.

Bone Marrow Transplant. 2019 Sep 26. doi: 10.1038/s41409-019-0700-4. [Epub ahead of print]

PMID:
31558787
38.

Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia.

Debureaux PE, Labopin M, Mamez AC, Lapusan S, Isnard F, Adaeva R, Bonnin A, Hirsch P, Delhommeau F, Battipaglia G, Duléry R, Malard F, Vekhoff A, Mohty M, Legrand O, Brissot E.

Bone Marrow Transplant. 2020 Feb;55(2):452-460. doi: 10.1038/s41409-019-0690-2. Epub 2019 Sep 25.

PMID:
31554931
39.

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT.

Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, Baron F, Ciceri F, Esteve J, Gorin NC, Spyridonidis A, Schmid C, Ciurea SO, Nagler A, Mohty M.

Haematologica. 2020 Jan;105(1):47-58. doi: 10.3324/haematol.2019.219790. Epub 2019 Sep 19.

40.

Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.

Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, Yakoub-Agha I, Chevallier P, Ganser A, Blaise D, Milpied N, Bruno L, Mailhol A, Mohty M, Nagler A.

Bone Marrow Transplant. 2020 Jan;55(1):224-232. doi: 10.1038/s41409-019-0673-3. Epub 2019 Sep 16.

PMID:
31527819
41.

Gut microbiota alteration during allogeneic haematopoietic cell transplantation: what can we do?

Malard F, Mohty M.

Br J Haematol. 2020 Feb;188(3):351-353. doi: 10.1111/bjh.16204. Epub 2019 Sep 16. No abstract available.

PMID:
31524291
42.

Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.

Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gülbas Z, Wallet HL, Corral LL, Mohty M, Koc Y, Yakoub-Agha I, Schmid C, El Cheikh J, Arat M, Forcade E, Dreger P, Rocha V, García GG, Chalandon Y, Ferra C, Orvain C, Robinson S, Montoto S, Sureda A.

Br J Haematol. 2019 Sep 9. doi: 10.1111/bjh.16182. [Epub ahead of print]

PMID:
31498883
43.

Infectious complications after post-transplantation cyclophosphamide and anti-thymocyte globulin-based haploidentical stem cell transplantation.

Mohty R, Brissot E, Battipaglia G, Ruggeri A, Dulery R, Bonnin A, Médiavilla C, Sestili S, Belhocine R, Vekhoff A, Ledraa T, Lapusan CS, Adaeva R, Isnard F, Legrand O, Mohty M, Malard F.

Br J Haematol. 2019 Nov;187(3):e64-e68. doi: 10.1111/bjh.16189. Epub 2019 Sep 5. No abstract available.

PMID:
31487392
44.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.

Shouval R, Fein JA, Labopin M, Kröger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A.

Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.

PMID:
31477550
45.

Exploring the microvascular impact of red blood cell transfusion in intensive care unit patients.

Hariri G, Bourcier S, Marjanovic Z, Joffre J, Lemarié J, Lavillegrand JR, Charue D, Duflot T, Bigé N, Baudel JL, Maury E, Mohty M, Guidet B, Bellien J, Blanc-Brude O, Ait-Oufella H.

Crit Care. 2019 Aug 30;23(1):292. doi: 10.1186/s13054-019-2572-9.

46.

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.

Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, de la Camara R, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Kröger N, Mohty M, Gratwohl A; Infectious Diseases Working Party EBMT.

Bone Marrow Transplant. 2020 Jan;55(1):126-136. doi: 10.1038/s41409-019-0624-z. Epub 2019 Aug 27.

47.

Relapsed refractory multiple myeloma: a comprehensive overview.

Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M.

Leukemia. 2019 Oct;33(10):2343-2357. doi: 10.1038/s41375-019-0561-2. Epub 2019 Aug 27. Review.

PMID:
31455853
48.

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.

Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Ali Hamidieh A, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitsky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D.

Hematol Oncol Stem Cell Ther. 2019 Aug 20. pii: S1658-3876(19)30055-X. doi: 10.1016/j.hemonc.2019.08.002. [Epub ahead of print]

49.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321. doi: 10.1016/j.bbmt.2019.08.015. Epub 2019 Aug 22. Review.

PMID:
31446199
50.

Hematopoietic Cell Transplant Consideration for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Patients.

El Fakih R, Savani B, Mohty M, Aljurf M.

Biol Blood Marrow Transplant. 2020 Jan;26(1):e16-e20. doi: 10.1016/j.bbmt.2019.08.010. Epub 2019 Aug 21. Review.

PMID:
31445182

Supplemental Content

Support Center